What is the Optimal antiplatElet and Anticoagulant Therapy in Patients With Oral Anticoagulation Undergoing revasculariSaTion 2.
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Acute Coronary Syndromes
- Atrial Fibrillations
- Bleeding
- Coronary Artery Diseases
- Heart Valve Prostheses
- Myocardial Infarction
- Stroke
- Design
- Observational Model: CohortTime Perspective: Prospective
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
The WOEST 2 Registry is a prospective, international, multi-centre, non-interventional, cohort study designed to recruit an unselected cohort of patients with atrial fibrillation and/or a heart valve prosthesis undergoing coronary revascularisation. Trial overview Name : WOEST 2 REGISTRY Target for ...
The WOEST 2 Registry is a prospective, international, multi-centre, non-interventional, cohort study designed to recruit an unselected cohort of patients with atrial fibrillation and/or a heart valve prosthesis undergoing coronary revascularisation. Trial overview Name : WOEST 2 REGISTRY Target for enrollment : 2200 patients Time frame for inclusion : within 72 hours after index PCI or coronary artery bypass grafting (CABG) Follow-up : 24 months Visits : 30 days, 12 and 24 months after index PCI or CABG
Tracking Information
- NCT #
- NCT02635230
- Collaborators
- St. Antonius Hospital
- Investigators
- Principal Investigator: Jurriën M ten Berg, MD, PhD St. Antonius Hospital Nieuwegein, the Netherlands Principal Investigator: Willem JM Dewilde, MD, PhD Imelda Hospital Bonheiden, Belgium
Get Well Soon